Combination of DBT and synthetic mammography reduces recall rates among women with non-dense breasts

Screening women with non-dense breasts with a combination of digital breast tomosynthesis (DBT) and 2D synthetic mammography (SM) leads to lower recall rates than standard digital mammography (DM), according to new findings published in Radiology.

The authors examined data from more than 28,000 patients who underwent breast cancer screening in Norway from 2016 to 2017. The median patient age was 59 years old. Approximately half were screened with DBT plus SM, and the other half was screened with DM.

Breast density assessments were performed on each patient using automated software by Volpara. Assessments were then categorized as Volpara Density Grade 1, 2, 3 or 4, rankings that are typically very close to BI-RADS classifications.

Overall, DBT plus SM resulted in lower recall rates for women in the VDG 1 (2.1% vs. 3.3%) and VDG 2 (3.2% vs. 4.3%) categories. No significant difference was detected for women in the VDG 3 or VDG 4 categories.

The adjusted relative risk for recall, a false-positive finding or screen-detected breast cancer all increased along with VDG categories when screening with DBT plus SM—no such trend was noted when screening occurred

“DBT plus SM with automated density assessment may be a responsive and effective combination for stratified risk-based screening for breast cancer, including supplemental screening techniques or more frequent screening among women with dense breasts,” wrote lead author Nataliia Moshina, MD, PhD, from the Cancer Registry of Norway, and colleagues. “More studies, combined with systematic reviews and meta-analyses, are needed to make evidence-based conclusions.”

The full analysis from Radiology is available here.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

Trimed Popup
Trimed Popup